Education

MD Medicine, University of Chicago, 1990
MS Epidemiology, University of Washington, 1996
BS Biology, Colby College, 1985

Contact

805-890-4210
catherine.stehman-breen@chromamedicine.com

View Website »

Bio

Catherine's research has focused on a ranges of areas including metabolic, cardiovascular, kidney and neurologic diseases including rare muscle disease. During her academic career, she managed the Clinical Research Training Program and developed the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in renal disease patients. Catherine's subsequent work has been to bring innovative therapeutics to patients with serious illnesses. Characterizing disease epidemiology has been an important component of this work.

Catherine received her medical degree from University of Chicago in 1990. She completed her residency and fellowship training at the University of Washington where she also received a Masters of Science degree in Epidemiology. She spent six years as a Faculty member in the Division of Nephrology at University of Washington. Her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in renal disease patients. Catherine is now Chief Executive Officer at Chroma Medicine. She also serves as an Independent Board member at Generation Bio, Tenaya Therapeutics and Dyne Therapeutics. Previously, she was Chief Research and Development Officer at Obsidian Therapeutics where she led discovery efforts for their engineered cell and gene therapies. Prior to that, Catherine was an Entrepreneur in Residence at Atlas Venture and Chief Medical Officer at Sarepta Therapeutics. In addition, Catherine held leadership roles of increasing responsibility at Regeneron and Amgen.